Get the Stockscreener App
6.525
1.16%
0.075
Inmune Bio Inc stock is traded at $6.525, with a volume of 328.77K.
It is up +1.16% in the last 24 hours and up +48.30% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$6.45
Open:
$6.52
24h Volume:
328.77K
Relative Volume:
1.22
Market Cap:
$144.68M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-3.9072
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+9.57%
1M Performance:
+48.30%
6M Performance:
-19.25%
1Y Performance:
-42.46%
1-Day Range:
$6.16
$6.565
1-Week Range:
$5.82
$6.83
52-Week Range:
$4.32
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
6.525 | 144.68M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
14,725 Shares in INmune Bio, Inc. (NASDAQ:INMB) Bought by Jane Street Group LLC - Defense World
Candel Therapeutics (NASDAQ:CADL) versus INmune Bio (NASDAQ:INMB) Head-To-Head Review - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Average Target Price from Analysts - Defense World
Praetorian PR LLC Increases Stake in INmune Bio Inc: A Strategic Move in Biotechnology - GuruFocus.com
How Do Things Look For INmune Bio Inc (NASDAQ: INMB) In The Short-Term? - Stocks Register
Analysts’ Revisions Show Improving Sentiment For Uranium Energy Corp (AMEX: UEC) - Stocks Register
How Do Things Look For Lithium Americas Corp (NewCo) (NYSE: LAC) In The Short-Term? - Stocks Register
What Did We Note About Insider Trading At AT&T, Inc (NYSE: T)? - Stocks Register
Watch Duty was downloaded 2 million times during this week’s LA fires - Yahoo! Voices
Retail investors account for 41% of TELA Bio, Inc.'s (NASDAQ:TELA) ownership, while institutions account for 28% - Yahoo Finance
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
How To Trade (INMB) - Stock Traders Daily
Immunis Closes $25 Million Series A-1 Financing Round - Yahoo Finance
ChargePoint Holdings, Inc. (CHPT) Stock Moves -0.89%: What You Should Know - Yahoo Finance
Astera Labs, Inc. (ALAB) Stock Moves -0.82%: What You Should Know - Yahoo Finance
Palantir Technologies Inc. (PLTR) Stock Moves -1.44%: What You Should Know - Yahoo Finance
Nu Holdings Ltd. (NU) Declines More Than Market: Some Information for Investors - Yahoo Finance
IGM Bio stock plunges as analysts downgrade (IGMS:NASDAQ) - Seeking Alpha
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? - Yahoo Finance
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine - Yahoo Finance
Moon Capital Management Liquidated CVS Health Corporation (CVS) with Modest Gain - Yahoo Finance
BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency - Yahoo Finance
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases - Yahoo Finance
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued? - Yahoo Finance
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - Yahoo Finance
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Yahoo Finance
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - Yahoo Finance
Clipper Realty Inc. (NYSE:CLPR) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Purchases 21,262 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Financial Survey: AIM ImmunoTech (NYSE:AIM) and INmune Bio (NASDAQ:INMB) - Defense World
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand - Yahoo Finance
Pivot Bio Announces Ryan Degnan as Head of Growth - Yahoo Finance
FluidForm Bio™ Announces Participation at Biotech Showcase and the 14th Annual LifeSci Partners Corporate Access Event - Yahoo Finance
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Kratos Defense & Security Solutions, Inc. (KTOS): A Bull Case Theory - Yahoo Finance
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Yahoo Finance
BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025 - Yahoo Finance
Barclays PLC Has $157,000 Stake in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Here's Why Investors Should Retain Molina Healthcare Stock for Now - Yahoo Finance
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Are Aerospace Stocks Lagging Leonardo DRS, Inc. (DRS) This Year? - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
InterDigital, Inc. (IDCC) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Child's Cure Genetic Research collaborates with Matica Bio to Drive Innovation in Pediatric Rare Disease Therapies - Yahoo Finance
BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC - Yahoo Finance
3 Chipmaker Stocks to Benefit From the Incoming Trump Administration - Yahoo Finance
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate - Yahoo Finance
Rubicon Technology (NASDAQ:RBCN) Stock Crosses Above 200-Day Moving Average – Time to Sell? - Defense World
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):